XBiotech's True Human™ antibody, Xilonix™, Featured at the World NSCLC Summit in Boston

XBiotech's XBiotech's Medical Director Michael Stecher, M.D., will give a presentation on Xilonix, at the 2015 World NSCLC Summit, being held June 23-24, 2015 in Boston, MA. Dr. Stecher's presentation, titled "Targeted Therapy Against Interleukin 1 Alpha in Patients with Refractory Non Small Cell Lung Cancer," will be part of a conference program featuring discussions of the latest trends in non-small cell lung cancer through case studies from early discovery to clinical development and will take place on the 23rd at 1:30 pm.

The presentation will provide an overview of Xilonix, a first in class True Human monoclonal antibody that neutralizes biological activity of interleukin-1 alpha. Recently published results from a subset of non-small cell lung cancer (NSCLC) patients treated at MD Anderson Cancer Center in Houston, TX, highlighted a potential synergy of Xilonix anti-IL-1 alpha therapy in NSCLC patients previously treated with EGFR inhibitors.

As reported in Investigational New Drugs, NSCLC patients with metastatic, refractory disease at baseline were treated with Xilonix monotherapy until disease progression. In addition to assessment of radiographic evidence of tumor response, changes in lean body mass, and quality of life, patients were followed for 24 months to assess survival. Radiographic evidence of anti-tumor effect was observed, in addition to improvements in lean body mass and quality of life. Furthermore, stratification by prior therapies revealed a median overall survival for patients treated with anti-EGFR therapy of 9.4 months compared to only 4.8 months for non-pretreated patients.

Dr. Stecher commented, "Patients with refractory Non-small Cell Lung Cancer have few effective treatment options. In the last line setting, resistance to anti-EGFR therapy is common, and may be due to the immunosuppressive effects of inflammation in the tumor microenvironment. The suggestion that Xilonix therapy may help overcome this resistance is highly encouraging and warrants sharing with stakeholders who have come to discuss key issues, and propose solutions to common challenges."